Solvent/detergent plasma: pharmaceutical characteristics and clinical experience

Journal of Thrombosis and Thrombolysis

Volumn 39, Issue 1, 2015, Pages 118-128

  Liumbruno, Giancarlo Maria ^a   Franchini, Massimo ^b  

^a SAN GIOVANNI CALIBITA FATEBENEFRATELLI HOSPITAL   (Italy)

^b CARLO POMA HOSPITAL   (Italy)

Author keywords

Clinical efficacy; Cost effectiveness; Fresh frozen plasma; Solvent detergent plasma; Transfusion related acute lung injury; Viral inactivation

Indexed keywords

DETERGENT; SOLVENT;

ACUTE LUNG INJURY; BLOOD COMPONENT THERAPY; CHEMISTRY; HUMAN; PLASMA; VIROLOGY; VIRUS INACTIVATION;

ACUTE LUNG INJURY; BLOOD COMPONENT TRANSFUSION; DETERGENTS; HUMANS; PLASMA; SOLVENTS; VIRUS INACTIVATION;

EID: 84927562038     PISSN: 09295305     EISSN: 1573742X     Source Type: Journal    
DOI: 10.1007/s11239-014-1086-1     Document Type: Review

References (95)

1. Horowitz B, Wiebe ME, Lippin A, Stryer MH (1985) Inactivation of viruses in labile blood derivatives: disruption of lipid-enveloped viruses by tri(n-butyl)phosphate detergent combinations. Transfusion 25:516–522
2. Prince AM, Horowitz B, Brotman B (1986) Sterilization of hepatitis and HTLV-III viruses by exposure to tri(n-butyl)phosphate and sodium cholate. Lancet 1:706–710
3. Dichtelmüller HO, Biesert L, Fabbrizzi F et al (2009) Robustness of solvent/detergent treatment of plasma derivatives: a data collection from Plasma Therapeutics Association member companies. Transfusion 49:1931–1943
4. Neurath AR, Vernon SK, Dobkin MB, Rubin BA (1972) Characterization of subviral components resulting from treatment of rabies virus with tri(n-buty1)phosphate. J Gen Virol 14:33–48
5. Omenn GS (2011) Data management and data integration in the HUPO plasma proteome project. Methods Mol Biol 696:247–257
6. Hellstern P, Solheim BG (2011) The use of solvent/detergent treatment in pathogen reduction of plasma. Transfus Med Hemother 38:65–70
7. Hellstern P, Sachse H, Schwinn H, Oberfrank K (1992) Manufacture and in vitro characterization of solvent/detergent-treated plasma. Vox Sang 63:178–185
8. Horowitz B, Bonomo R, Prince AM, Chin SN, Brotman B, Shulman RW (1992) Solvent/detergent-treated plasma. A virus-inactivated substitute for fresh frozen plasma. Blood 79:826–833
9. Biesert L, Shartono H (1998) Solvent/detergent treatment of human plasma: a very robust method for virus inactivation. Validation of virus safety of Octaplas. Vox Sang 74(Suppl 1):207–212
10. Prowse C (2009) Properties of pathogen-inactivated plasma components. Transfus Med Rev 23:124–133
11. Directorate for the Quality of Medicines & HealthCare of the Council of Europe (EDQM) (2007) 07/2008:1646. Human plasma (pooled and treated for virus inactivation). Plasma humanum coagmentatum conditumque ad exstinguendum virum. In: Council of Europe (ed) European Pharmacopoeia, Supplement 6.2, 6th edn. Council of Europe, Strasbourg Cedex, France, p 3760–3762. http://gendocs.ru/docs/5/4959/conv_1/file1.pdf. Accessed 15 March 2014
12. Pelletier JP, Transue S, Snyder EL (2006) Pathogen inactivation techniques. Best Pract Res Clin Haematol 19:205–242
13. Burnouf T, Goubran HA, Radosevich M, Sayed MA, Gorgy G, El-Ekiaby M (2006) A process for solvent/detergent treatment of plasma for transfusion at blood centers that use a disposable bag system. Transfusion 46:2100–2108
14. El-Ekiaby M, Sayed MA, Caron C et al (2010) Solvent-detergent filtered (S/D-F) fresh frozen plasma and cryoprecipitate minipools prepared in a newly designed integral disposable processing bag system. Transfus Med 20:48–61
15. Jilma-Stohlawetz P, Kursten FW, Horvath M et al (2013) Recovery, safety, and tolerability of a solvent/detergent-treated and prion-safeguarded transfusion plasma in a randomized, crossover, clinical trial in healthy volunteers. Transfusion 53:1906–1917
16. Heger A, Svae TE, Neisser-Svae A, Jordan S, Behizad M, Römisch J (2009) Biochemical quality of the pharmaceutically licensed plasma OctaplasLG after implementation of a novel prion protein (PrPSc) removal technology and reduction of the solvent/detergent (S/D) process time. Vox Sang 97:219–225
17. Liumbruno GM, Sodini ML, Grazzini G, Tuscan Transfusion System (2008) Recommendations from the Tuscan Transfusion System on the appropriate use of solvent/detergent-inactivated fresh-frozen plasma. Blood Transfus 6:25–36
18. Koenigbauer UF, Eastlund T, Day JW (2000) Clinical illness due to parvovirus B19 infection after infusion of solvent/detergent-treated pooled plasma. Transfusion 40:1203–1206
19. Liumbruno GM, Catalano L, Piccinini V, Pupella S, Grazzini G (2009) Reduction of the risk of bacterial contamination of blood components through diversion of the first part of the donation of blood and blood components. Blood Transfus 7:86–93
20. Chou ML, Wu YW, Su CY, Lee LW, Burnouf T (2012) Impact of solvent/detergent treatment of plasma on transfusion-relevant bacteria. Vox Sang 102:277–284
21. Sharma AD, Sreeram D, Erb T, Grocott HP (2000) Solvent-detergent fresh frozen plasma. A superior alternative to standard fresh frozen plasma? J Cardiothorac Vasc Anesth 14:712–717
22. Hellstern P (2004) Solvent/detergent-treated plasma: composition, efficacy, and safety. Curr Opin Hematol 11:346–350
23. Solheim BG, Seghatchian J (2006) Update on pathogen reduction technology for therapeutic plasma: an overview. Transfus Apher Sci 35:83–90
24. Piquet Y, Janvier G, Selosse P et al (1992) Virus inactivation of fresh frozen plasma by a solvent detergent procedure: biological results. Vox Sang 63:251–256
25. Sinnott P, Bodger S, Gupta A, Brophy M (2004) Presence of HLA antibodies in single-donor-derived fresh frozen plasma compared with pooled, solvent detergent-treated plasma (Octaplas). Eur J Immunogenet 31:271–274
26. Sachs UJ, Kauschat D, Bein G (2005) White blood cell reactive antibodies are undetectable in solvent/detergent plasma. Transfusion 45:1628–1631
27. Flesland O, Seghatchian J, Solheim BG (2003) The Norwegian Plasma Fractionation Project: a 12-year clinical and economic success story. Transfus Apher Sci 28:93–100
28. Steinsvåg CT, Espinosa A, Flesland O (2013) Eight years with haemovigilance in Norway. What have we learnt? Transfus Apher Sci 49:548–552
29. Thevis M, Krug O, Geyer H et al (2013) Monitoring drug residues in donor blood/plasma samples using LC-(MS)/MS: a pilot study. Drug Test Anal 5:380–383
30. Yoshida T, Shevkoplyas SS (2010) Anaerobic storage of red blood cells. Blood Transfus 8:220–236
31. Feys HB, Van Aelst B, Devreese K et al (2014) Oxygen removal during pathogen inactivation with riboflavin and UV light preserves protein function in plasma for transfusion. Vox Sang 106:307–315
32. Seltsam A, Müller TH (2013) Update on the use of pathogen-reduced human plasma and platelet concentrates. Br J Haematol 162:442–454
33. Grazzini G, Rossi G, Rafanelli D et al (2008) Quality control of recovered plasma for fractionation: an extensive Italian study. Transfusion 48:1459–1468
34. Heger A, Kannicht C, Römisch J, Svae TE (2007) Normal levels of ADAMTS13 and factor H are present in the pharmaceutically licensed plasma for transfusion (Octaplas) and in the universally applicable plasma (Uniplas) in development. Vox Sang 92:206–212
35. ®). Anesth Analg 94:1127–1131
36. Solheim BG, Bergan A, Brosstad F, Innes R, Svennevig JL (2003) Fibrinolysis during liver transplant and use of solvent/detergent virus-inactivated plasma (ESDEP/Octaplas). Anesth Analg 96:1230–1231 author reply 1231–1232
37. Beeck H, Hellstern P (1998) In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma. Vox Sang 74(Suppl 1):219–223
38. Magner JJ, Crowley KJ, Boylan JF (2007) Fatal fibrinolysis during orthotopic liver transplantation in patients receiving solvent/detergent-treated plasma (Octaplas). J Cardiothorac Vasc Anesth 21:410–413
39. Sandler SG (2007) It is time to bring back solvent-detergent plasma. Curr Opin Hematol 14:640–641
40. Salge-Bartels U, Breitner-Ruddock S, Hunfeld A, Seitz R, Heiden M (2006) Are quality differences responsible for different adverse reactions reported for SD-plasma from USA and Europe? Transfus Med 16:266–275
41. Thiéry G, Jacobs F, Bussel A et al (2004) Acute hyperphosphatemia after plasma exchange with S/D-treated plasma. Transfusion 44:947–948
42. Flamholz R, Jeon HR, Baron JM, Baron BW (2000) Study of three patients with thrombotic thrombocytopenic purpura exchanged with solvent/detergent-treated plasma: is its decreased protein S activity clinically related to their development of deep venous thromboses? J Clin Apher 15:169–172
43. Yarranton H, Cohen H, Pavord SR, Benjamin S, Hagger D, Machin SJ (2003) Venous thromboembolism associated with the management of acute thrombotic thrombocytopenic purpura. Br J Haematol 121:778–785
44. Rizvi MA, Vesely JN, George JN et al (2000) Complications of plasma exchange in 71 consecutive patients treated for clinically suspected thrombotic thrombocytopenic purpura–haemolytic–uremic syndrome. Transfusion 40:896–901
45. McMinn JR Jr, Thomas IA, Terrel DR, Duvall D, Vesely SK, George JN (2003) Complications of plasma exchange in thrombotic thrombocytopenic purpura–hemolytic uremic syndrome: a study of 78 additional patients. Transfusion 43:415–416
46. Rock G (2011) A comparison of methods of pathogen inactivation of FFP. Vox Sang 100:169–178
47. Picker SM (2013) Current methods for the reduction of blood-borne pathogens: a comprehensive literature review. Blood Transfus 11:343–348
48. Benjamin RJ, McLaughlin LS (2012) Plasma components: properties, differences, and uses. Transfusion 52(Suppl):9S–19S
49. Hacquard M, Lecompte T, Belcour B et al (2012) Evaluation of the hemostatic potential including thrombin generation of three different therapeutic pathogen-reduced plasmas. Vox Sang 102:354–361
50. Singh Y, Sawyer LS, Pinkoski LS et al (2006) Photochemical treatment of plasma with amotosalen and long-wavelength ultraviolet light inactivates pathogens while retaining coagulation function. Transfusion 46:1168–1177
51. Smith J, Rock G (2010) Protein quality in Mirasol pathogen reduction technology–treated, apheresis-derived fresh-frozen plasma. Transfusion 50:926–931
52. Zeiler T, Wittmann G, Zimmermann R, Hintz G, Huhn D, Riess H (2000) The effect of virus inactivation on coagulation factors in therapeutic plasma. Br J Haematol 111:986–987
53. Doyle S, O’Brien P, Murphy K, Fleming C, O’Donnell J (2003) Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma. Blood Coagul Fibrinolysis 14:283–287
54. Aznar JA, Molina R, Montoro JM (1999) Factor VIII/von Willebrand factor complex in methylene blue-treated fresh plasma. Transfusion 39:748–750
55. Osselaer JC, Debry C, Goffaux M et al (2008) Coagulation function in fresh-frozen plasma prepared with two photochemical treatment methods: methylene blue and amotosalen. Transfusion 48:108–117
56. Yarranton H, Lawrie AS, Purdy G, Mackie IJ, Machin SJ (2004) Comparison of von Willebrand factor antigen, von Willebrand factor-cleaving protease and protein S in blood components used for treatment of thrombotic thrombocytopenic purpura. Transfus Med 14:39–44
57. Schlenke P, Hervig T, Isola H et al (2008) Photochemical treatment of plasma with amotosalen and UVA light: process validation in three European blood centers. Transfusion 48:697–705
58. Larrea L, Calabuig M, Roldan V et al (2009) The influence of riboflavin photochemistry on plasma coagulation factors. Transfus Apher Sci 41:199–204
59. Inbal A, Epstein O, Blickstein D, Kombrot N, Brenner B, Martinowitz U (1993) Evaluation of solvent/detergent treated plasma in the management of patients with acquired coagulation disorders. Blood Coagul Fibrinolysis 4:559–604
60. Horowitz MS, Pehta JC (1998) SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available. Vox Sang 74(Suppl 1):231–235
61. Santagostino E, Mancuso ME, Morfini M et al (2006) Solvent/detergent plasma for prevention of bleeding in recessively inherited coagulation disorders: dosing, pharmacokinetics and clinical efficacy. Haematologica 91:634–639
62. Chowdhury P, Saayman AG, Paulus U, Findlay GP, Collins PW (2004) Efficacy of standard dose and 30 ml/kg fresh frozen plasma in correcting laboratory parameters of haemostasis in critically ill patients. Br J Haematol 125:69–73
63. Holland LL, Brooks JP (2006) Toward rational fresh frozen plasma transfusion. Am J Clin Pathol 126:133–139
64. Levi M, Toh CH, Thachil J, Watson HG (2009) Guidelines for the diagnosis and management of disseminated intravascular coagulation. British Committee for Standards in Haematology. Br J Haematol 145:24–33
65. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party (2011) Recommendations for the transfusion management of patients in the peri-operative period I. The pre-operative period. Blood Transfus 9:19–40
66. Liumbruno GM, Bennardello F, Lattanzio A, Piccoli P, Rossetti G, Italian Society of Transfusion Medicine and Immunohaematology (SIMTI) Working Party (2011) Recommendations for the transfusion management of patients in the peri-operative period. II. The intra-operative period. Blood Transfus 9:189–217
67. Lerner RG, Nelson J, Sorcia E (2000) Evaluation of solvent/detergent treated plasma in patients with a prolonged prothrombin time. Vox Sang 79:161–167
68. Beck KH, Mortelsmans Y, Kretschmer VV, Höltermann W, Lukasewitz P (2000) Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions. Infusionsther Transfusionsmed 27:144–148
69. Williamson LM, Llewelyn CA, Fisher NC et al (1999) A randomized trial of solvent/detergent-treated and standard fresh-frozen plasma in the coagulopathy of liver disease and liver transplantation. Transfusion 39:1227–1234
70. Solheim BG (2006) Universal pathogen-reduced plasma in elective open-heart surgery and liver resection. Clin Med Res 4:209–217
71. Solheim BG, Granov DA, Juravlev VA et al (2005) Universal fresh-frozen plasma (Uniplas): an exploratory study in adult patients undergoing elective liver resection. Vox Sang 89:19–26
72. Chekrizova V, Murphy WG (2006) Solvent–detergent plasma: use in neonatal patients, in adult and paediatric patients with liver disease and in obstetric and gynaecological emergencies. Transfus Med 16:85–91
73. Freeman JW, Williamson LM, Llewelyn C et al (1998) A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation. Vox Sang 74(Suppl 1):225–229
74. Bindi ML, Miccoli M, Marietta M et al (2013) Solvent detergent vs. fresh frozen plasma in cirrhotic patients undergoing liver transplant surgery: a prospective randomized control study. Vox Sang 105:137–143
75. Lepri D, Capuzzo E, Mattioli AV et al (2013) Clinical use of virally inactived plasma. The experience of Blood Transfusion Unit in Mantova, Italy. Recenti Prog Med 104:106–111
76. Haubelt H, Blome M, Kiessling AH et al (2002) Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery. Vox Sang 82:9–14
77. Wieding JU, Rathgeber J, Zenker D (1999) Prospective randomized and controlled study on solvent/detergent versus methylene blue/light virus-inactivated plasma. Transfusion 39(S10):23s. doi:10.1111/j.1537-2995.1999.tb05925.x
78. Tollofsrud S, Noddeland H, Svennevig JL, Bentsen G, Mollnes TE, Solheim BG (2003) Universal fresh frozen plasma (Uniplas): a safe product in open-heart surgery. Intensive Care Med 29:1736–1743
79. De Silvestro G, Bagatella P, Tison T et al (2007) Virus-inactivated—Plasmasafe: a one-year experience. Blood Transfus 5:134–142
80. McCarthy LJ (2006) The experience of treating patients with thrombotic thrombocytopenic purpura with solvent detergent plasma. Br J Haematol 133:107
81. Scully M, Longair I, Flynn M, Berryman J, Machin SJ (2007) Cryosupernatant and solvent detergent fresh frozen plasma (octaplas) usage in a single centre in acute thrombotic thrombocytopenic purpura. Vox Sang 93:154–158
82. Edel E, Al-Ali HK, Seeger S, Kauschat D, Matthes G (2010) Efficacy and safety profile of solvent/detergent plasma in the treatment of acute thrombotic thrombocytopenic purpura: a single-center experience. Transfus Med Hemother 37:13–19
83. Andreu G (2010) France: solvent/detergent plasma. In: AuBuchon JP, Prowse CV (eds) Pathogen inactivation: the penultimate paradigm shift. AABB Press, Bethesda, pp 137–151
84. Krusius T, Auvinen M-K, Tuimala (2010) Introduction of octaplas in clinical use decreased the rate of serious adverse reactions. Vox Sang 99(Suppl 1):P-1018
85. Baudoux E, Margraff U, Coenen A et al (1998) Hemovigilance: clinical tolerance of solvent-detergent treated plasma. Vox Sang 74Ssuppl 1):237-239
86. Bolton-Maggs PH, Cohen H (2013) Serious Hazards of Transfusion (SHOT) haemovigilance and progress is improving transfusion safety. Br J Haematol 163:303–314
87. Österreichisches Bundesinstitut für Gesundheitswesen (2004) Hämovigilanz Jahresbericht 2004. http://www.goeg.at/cxdata/media/download/berichte/HaemJB_2004.pdf. Accessed 18 February 2014
88. Facco G, Pupella S, Piccinini V, Catalano L, Vaglio S (2012) I dati italiani di emovigilanza. Blood Transfus 10(Suppl 1):s57–s58
89. AuBuchon JP, Birkmeyer JD (1994) Safety and cost-effectiveness of solvent-detergent-treated plasma. In search of a zero-risk blood supply. JAMA 272:1210–1214
90. Pereira A (1999) Cost-effectiveness of transfusing virus inactivated plasma instead of standard plasma. Transfusion 39:479–487
91. Jakson BR, AuBuchon JP, Birkmeyer JD (1999) Update of cost-effectiveness analysis for solvent-detergent-treated plasma. JAMA 282:329
92. Riedler GF, Haycox AR, Duggan AK, Dakin HA (2003) Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma. Vox Sang 85:88–95
93. ®) versus fresh frozen plasma (FFP) in critically Ill patients in the UK. Transfus Apher Sci 43:251–259
94. Membe SK, Coyle D, Husereau D, Cimon K, Tinmouth A, Normandin S (2009) Octaplas compared with fresh frozen plasma to reduce the risk of transmitting lipid-enveloped viruses: an economic analysis and budget impact analysis. http://www.cadth.ca/media/pdf/I4002_Octaplas%20versus%20FFP_L4_e_April%202009.pdf. Accessed 17 February 2014
95. ®) versus fresh-frozen plasma (FFP) in any patient receiving transfusion in Canada. Transfus Apher Sci. doi:10.1016/j.transci.2013.04.045